Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Specific binding of phospholipid platelet-activating factor by human platelets.

F H Valone, E Coles, V R Reinhold

    Journal of Immunology (Baltimore, Md. : 1950)
    |October 1, 1982
    PubMed
    Summary

    Platelet-activating factor (AGEPC) rapidly binds to human platelets, initiating aggregation via high-affinity sites. Prolonged exposure leads to functional deactivation and reduced binding, despite remaining binding sites.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The impact of an online, lifestyle intervention programme on the lives of patients with a rheumatic and musculoskeletal disease: a pilot study.

    Rheumatology (Oxford, England)·2024
    Same author

    Etiopathogenesis and prognostic implications of autoimmune hemolytic anemia association with chronic lymphocytic leukemia B.

    Journal of medicine and life·2019
    Same author

    Prognosis Factors in Chronic Lymphocytic Leukemia.

    Journal of medicine and life·2019
    Same author

    Investigating community-based health and health promotion for homeless people: a mixed methods review.

    Health education research·2012
    Same author

    Lenalidomide enhancement of human T cell functions in human immunodeficiency virus (HIV)-infected and HIV-negative CD4 T lymphocytopenic patients.

    Clinical and experimental immunology·2012
    Same author

    Bispecific Antibody MDX-210 for Treatment of Advanced Ovarian and Breast Cancer.

    Methods in molecular medicine·2011

    Area of Science:

    • Biochemistry
    • Hematology
    • Cell Biology

    Background:

    • Platelet-activating factor (AGEPC) is a phospholipid involved in platelet activation.
    • Understanding AGEPC binding is crucial for comprehending platelet aggregation mechanisms.

    Purpose of the Study:

    • To characterize the binding kinetics and specificity of AGEPC to human platelets.
    • To investigate the relationship between AGEPC binding and platelet aggregation.
    • To explore the phenomenon of AGEPC-induced platelet deactivation.

    Main Methods:

    • Scatchard plot analysis of [3H]AGEPC binding to platelets.
    • Assessment of analogue inhibition of AGEPC binding and aggregation.
    • Functional deactivation assays following AGEPC exposure.

    Related Experiment Videos

    Main Results:

    • AGEPC binding is rapid (>80% in 2 min) and initiates platelet aggregation.
    • Two binding sites identified: a high-affinity saturable site (KD=37 nM) and a non-receptor uptake site.
    • Specific structural features (ether linkage, short-chain fatty acid, choline moiety) are critical for binding and aggregation.
    • Platelet deactivation occurs within 90 sec at 37°C, with reduced aggregation and binding, yet some sites remain.

    Conclusions:

    • Human platelets possess specific, high-affinity binding sites for AGEPC that mediate aggregation.
    • AGEPC binding and subsequent aggregation are structure-dependent.
    • Platelets undergo functional deactivation upon prolonged AGEPC exposure, indicating complex regulatory mechanisms.